关于新加坡心力衰竭患者药物成本讨论的患者经验和偏好:一种定性调查
Qianyu Shen1, Dennis Chin Wee Chua2, Po Fun Chan3
1Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
Patient preference and adherence
|February 27, 2025
概括
新加坡心力衰竭患者希望与医生讨论药物费用,但很少有人这样做. 解决临床医生主动性和时间限制等障碍是明智决策和降低财务负担的关键.
科学领域:
- 卫生经济学 卫生经济学
- 以患者为中心的护理
- 药物经济学 药物经济学
背景情况:
- 新型药物成本的上升给心力衰竭患者带来了财务毒性.
- 患者和临床医生之间关于药费的讨论很少发生.
- 财务负担会影响患者的坚持和生活质量.
研究的目的:
- 调查心力衰竭患者在新加坡关于药物成本讨论的经验和偏好.
- 找出这些对话的障碍.
- 制定战略,鼓励关于药物开支的公开对话.
主要方法:
- 用开放式问题对心力衰竭患者进行定性调查.
- 2022年从新加坡医院门诊处招聘.
- 患者反应的传统内容分析.
主要成果:
- 在48名心力衰竭患者中,93.8%的患者希望讨论药物费用,因为担心负担能力和知情决策.
- 只有8.3%的患者报告与临床医生定期讨论成本.
- 确定了关键障碍:缺乏临床医生的主动性,有限的成本意识和时间限制.
结论:
- 新加坡的心力衰竭患者表达了强烈的愿望,希望与他们的临床医生讨论药物费用.
- 患者的愿望和成本讨论的现实之间存在很大的差距.
- 克服已识别的障碍对于实现明智的药物选择和减轻财务毒性至关重要.
相关概念视频
Heart Failure Drugs: β-Blockers
308
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
308
Heart Failure Drugs: Inotropic Agents
498
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
498
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
370
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
370
Heart Failure Drugs: Diuretics
332
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
332
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Hormonal Regulation
32.8K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K


